JaLCDOI 10.18926/AMO/30757
フルテキストURL fulltext.pdf
著者 Noguchi, Hirofumi| Matsumoto, Shinichi|
抄録 <p>The direct intracellular delivery of proteins has, until recently, been difficult to achieve, due primarily to the bioavailability barrier of the plasma membrane. During the past 15 years, a variety of peptides called protein transduction domains (PTDs) or cell penetrating peptides (CPPs), have been characterized for their ability to translocate into live cells. The most commonly studied are homeodomain transcription factors such as Antennapedia, the herpes simplex virus (HSV) type 1 protein VP22, and the human immunodeficiency virus (HIV-1) transactivator TAT protein. Recently, polyarginine exhibits even greater efficiency in terms of delivery of several peptides and proteins. Numerous examples of biologically active full-length proteins and peptides have been delivered to cells and tissues, both in vitro and in vivo. These studies offer new avenues for treatment of several diseases. The main mechanism of protein transduction is an electrostatic interaction with the plasma membrane, penetration into cells by macropinocytosis, and a release to cytoplasm and nuclei by retrograde transport. Moreover, the intercellular transfer of endogenous transcription factors, such as TAT and homeoproteins, seems to point to an original and important mode of signal transduction. The protein transduction systems have opened up several possibilities, not only for the development of new peptide/protein drugs but also for consideration of their physiological and developmental implications.</p>
キーワード protein transduction protein transduction domain cell penetrating peptide macropinocytosis intercellular transfer
Amo Type Review
発行日 2006-02
出版物タイトル Acta Medica Okayama
60巻
1号
出版者 Okayama University Medical School
開始ページ 1
終了ページ 11
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16508684
Web of Science KeyUT 000235538900001
JaLCDOI 10.18926/AMO/30733
フルテキストURL fulltext.pdf
著者 Noguchi, Hirofumi| Matsumoto, Shinichi| Matsushita, Masayuki| Kobayashi, Naoya| Tanaka, Koichi| Matsui, Hideki| Tanaka, Noriaki|
抄録 The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen is a significant breakthrough that allows the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year ; however, the rate is reduced to 50% at 3 years, attributed to prolonged tacrolimus exposure. Recently, immunosuppression agents such as cyclosporine, mycophenolate mofetil, and the novel agent FTY 720 have been used instead of tacrolimus. Lymphocytedepleting antibodies such as anti-thymocyte globulin, alemtuzumab, and hOKT3gamma 1 (ala, ala) have been launched, and a costimulatory blockade of anti-CD40 monoclonal antibodies and CTLA4-Ig will be attempted in the near future. Moreover, the potential of a novel immunosuppressing peptide could now be realized using new technology called the protein transduction system. In this review, we show some of the most recent contributions to the advancement of knowledge in this field.
キーワード islet transplantation steroid-free Edmonton protocol protein transduction syst
Amo Type Review
発行日 2006-04
出版物タイトル Acta Medica Okayama
60巻
2号
出版者 Okayama University Medical School
開始ページ 71
終了ページ 76
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16680182
Web of Sience KeyUT 000237001900001